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Abstract
Chlamydiae are obligate intracellular bacteria, developing inside host cells within
chlamydial inclusions. From these inclusions, the chlamydiae secrete proteins into
the host cell cytoplasm. A pathway through which secreted proteins can be
delivered is the type III secretion system (T3SS). The T3SS is common to several
gram-negative bacteria and the secreted proteins serve a variety of functions often
related to the modulation of host signalling. To identify new potentially secreted
proteins, the cytoplasm was extracted from Chlamydia trachomatis L2-infected
HeLa cells, and two-dimensional polyacrylamide gel electrophoresis proﬁles of
[
35S]-labelled chlamydial proteins from this extract were compared with proﬁles of
chlamydial proteins from the lysate of infected cells. In this way, CT621 was
identiﬁed. CT621 is a member of a family of proteins containing a domain of
unknown function DUF582 that is only found within the genus Chlamydia.
Immunoﬂuorescence microscopy and immunoblotting demonstrated that CT621
is secreted late in the chlamydial developmental cycle and that it is the ﬁrst
chlamydial protein found to be localized within both the host cell cytoplasm and
the nucleus. To determine whether CT621 is secreted through the T3SS, an
inhibitor of this apparatus was added to the infection medium, resulting in
retention of the protein inside the chlamydiae. Hence, the so far uncharacterized
CT621 is a new type III secretion effector protein.
Introduction
Chlamydia are obligate intracellular bacteria with a unique
biphasic developmental cycle. The infectious elementary
bodies (EB) enter the host cell cytoplasm, where they
differentiate into metabolically active reticulate bodies (RB)
inside a membrane-bound vacuole, the chlamydial inclu-
sion. The RB multiply and the developmental cycle is
completed by asynchronous redifferentiation of RB into EB
that are released upon lysis of the host cell (Moulder, 1991;
Abdelrahman & Belland, 2005).
In electron microscopic studies, Matsumoto and collea-
gues observed projections on the chlamydial surface (Gre-
gory et al., 1979; Matsumoto, 1982). These projections
emerge from beneath depressions of the bacterial plasma
membrane, span the periplasmic space and extend out of the
outer membrane, where they end with a pointed tip
(Nichols et al., 1985). Based on the discovery of genes
encoding a type III secretion system (T3SS) in Chlamydia
(Hsia et al., 1997), the chlamydial surface projections were
considered to represent type III secretion (T3S) apparatuses
(Bavoil & Hsia, 1998).
The T3SS has certain speciﬁc characteristics: ﬁrstly, it
allows translocation of proteins termed ‘effectors’, across
both bacterial membranes and the eukaryotic cell mem-
brane. Secondly, secretion is independent of the general
secretory pathway, Sec; however, a noncleavable amino-
terminal signal sequence might be localized in the secreted
proteins. Finally, the secretion apparatus has a distinctive
structure, which indicates that transport through this path-
way occurs in a single step (Hueck, 1998; Cornelis, 2006).
When the T3SS is assembled and the effector molecules are
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the bacterial attack (Feldman & Cornelis, 2003).
The T3SS is essential for numerous gram-negative bacter-
ial species, creating a pathway through which effector
proteins can be delivered into eukaryotic cells directly from
pathogens such as Shigella, Salmonella and Yersinia (Hueck,
1998).
While the composition of the T3S apparatus is conserved
among bacterial species, a diverse array of effector proteins
is delivered to the host cell cytoplasm through this pathway.
The effectors modulate or interfere with many of the host
cellular functions, both after or during a bacterial invasion
(Kubori & Galan, 2003; Zurawski et al., 2006), and in the
same way, they are also used in further development and
maintenance of infections (Haraga & Miller, 2003; Okuda
et al., 2005). One functional characteristic common to
several of the type III secreted proteins is mimicking the
function of host cell proteins, a property that enables
pathogenic bacteria to exploit the eukaryotic ubiquitination
and small ubiquitin-like modiﬁer systems (Hotson et al.,
2003; Angot et al., 2007).
As for other gram-negative bacteria, the presumed func-
tion of the chlamydial T3SS is to establish and maintain an
infection. Among the proteins known to be secreted from
the chlamydiaeinsidethe inclusions andthroughthe T3SSis
the Chlamydia outer protein N (CopN), which has a high
degree of sequence similarity to Yersinia YopN and acts as a
regulator of the T3SS. CopN has been demonstrated to be
associated with the chlamydial inclusion membrane and can
be secreted by the T3SS of Yersinia (Fields & Hackstadt,
2000).
Based on the universality of the T3SS among gram-
negative bacteria, the ability of chlamydial proteins to be
secreted through the T3SS of another pathogen was used to
suggest several other new chlamydial T3S effectors. Using
this approach, it was proposed that the Chlamydia protein
associating with death domains (CADD) is a putative
substrate for the T3SS (Subtil et al., 2005). A number of
additional chlamydial proteins secreted through the T3SS
have been described, among them the translocated actin-
recruiting phosphoprotein (Tarp) (Clifton et al., 2004) and
the family of Inc proteins (Subtil et al., 2001; Rockey et al.,
2002).
It has been demonstrated that the chlamydial T3SS can be
blocked by small molecule inhibitors of the Yersinia T3SS,
belonging to a class of acylated hydrazones of salicylalde-
hydes. This effect was observed in both Chlamydia tracho-
matis (Muschiol et al., 2006; Wolf et al., 2006) and
Chlamydia pneumoniae (Bailey et al., 2007). Treatments
with N0-(3,5-dibromo-2-hydroxybenzylidene)-4-nitroben-
zohydrazide (designated compound 1–C1 or INP0007),
INP0400 or INP0010 prevented the secretion of C. tracho-
matis IncA, IncG, Tarp and CADD (Muschiol et al., 2006;
Wolf et al., 2006), and of C. pneumoniae IncB and IncC
(Bailey et al., 2007). The inhibitors also exhibited a dose-
dependent effect on chlamydial growth and development, a
ﬁnding that might reﬂect an involvement of T3S effectors in
the developmental cycle (Wolf et al., 2006; Peters et al.,
2007).
As described (Hobolt-Pedersen et al., 2006), extraction
buffer I from the ProteoExtract
TM subcellular proteome
extraction kit (Calbiochem, San Diego, CA) can be used to
extract the cytoplasm of infected host cells while the
chlamydiae are retained. In the analysis of extraction efﬁ-
ciency, the secreted chlamydial protease-like activity factor
(CPAF), which has a predicted signal peptidase cleavage site
indicative of Sec-dependent secretion (Zhong et al., 2001;
Shaw et al., 2002), was one of the proteins investigated. With
antibodies reacting against CPAF, Chlamydia major outer
membrane protein (MOMP) and Chlamydia cytoplasmic
protein GroEL, it was demonstrated that whereas the host
cytoplasm with its content of CPAF and potentially other
secreted chlamydial proteins was extracted with buffer I, the
RB and EB membranes remained intact during the proce-
dure.
Comparing the two-dimensional polyacrylamide gel elec-
trophoresis (2D-PAGE) proﬁle of chlamydial proteins from
the cytoplasmic extract with that of chlamydial proteins
from infected cells, we identiﬁed a cleavage product of
CT621 being secreted into the cytoplasm of infected host
cells. CT621 is a member of the Chlamydia-speciﬁc family of
proteins characterized by having a domain of unknown
function, DUF582. With speciﬁc antibodies, we visualized
the localization of CT621 in both the cytoplasm and the
nucleus of infected cells. Based on treatments of infected
cells with the T3SS inhibitor N0-(3,5-dibromo-2-hydroxy-
benzylidene)-4-nitrobenzohydrazide, C1, the secretion of
CT621 is proposed to occur through the C. trachomatis T3S
pathway.
Materials and methods
Cell culture and infection
HeLa cells [American Type Culture Collection (ATCC),
Rockville, MD], found to be free of mycoplasmas by
Hoechst no. 33258 staining, were cultivated in Roswell Park
Memorial Institute (RPMI)-1640 (Gibo BRL, Grand Island,
NY) supplemented with 10% foetal calf serum (heat-inacti-
vated, sterile-ﬁltered) and 10mgmL
 1 gentamicin at 371Ci n
a5 %C O 2 atmosphere.
The cells were infected with either 1 or 0.5 inclusion-
forming units (IFUs) per cell of C. trachomatis serovar L2
(434/Bu) from the ATCC. The medium supplying the
infected cells was supplemented with 1mgmL
 1 cyclohex-
imide.
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35S]-
methionine/cysteine
Thirty-six to 38 hours postinfection (hpi), the chlamydial
proteins were radioactively labelled in a methionine/cy-
steine-free RPMI-1640 medium containing 40mgmL
 1
cycloheximide and 100mCimL
 1 [
35S]-methionine/cysteine
(Promix from GE Healthcare, Little Chalfont, UK). After the
2-h labelling period, the cells were washed with phosphate-
buffered saline beforelysis using a 2D-lysis buffercontaining
7M urea, 2M thiourea, 4%w/v 3-[(3-chloramidopropyl)
dimethylammonium]-1-propanesulphonate, 40mM Tris-
base, 65mM dithioerythritol and 2%v/v Pharmalyte pH
3–10 (GE Healthcare).
Extraction procedures
Cytoplasmic extraction from HeLa cells infected with
C. trachomatis L2, 1IFU per cell, was performed using
extraction buffer I from the ProteoExtract
TM subcellular
proteome extraction kit (Calbiochem) in accordance with
the manufacturer’s instructions. The infected cells were
washed twice and the cytoplasmic fraction was extracted
usingbufferIsupplementedwith a protease inhibitorcocktail
(provided with the extraction kit) and 1mM NaVO3 for
10min at 41C under gentle agitation. The proteins from the
extractwereprecipitatedwith80% acetonefor1hat  201C.
Afterwards, the precipitated samples were centrifuged at
15000g (at 01C) for 10min and the pellets were dried.
Extraction of the membrane/organelle and nuclear frac-
tions was performed using extraction buffers II and III from
the same extraction kit in accordance with the manufac-
turer’s protocol. Subsequently, the remaining cytoskeletal
fraction was dissolved in a sodium dodecyl sulphate (SDS)
sample buffer.
2D-PAGE
The acetone-precipitated cytoplasmic fraction of infected
cells was dissolved in a 2D-lysis buffer, which was also used
for the harvest of infected and uninfected cell lysates. The
samples were separated by 2D-gel electrophoresis according
to Vandahl et al. (2001).
Following separation, the gels were ﬁxed in a solution
containing 10% acetic acid and 25% isopropanol for 30min
and vacuum dried. The dried gels were placed on phosphor-
imager screens (GE Healthcare) for 1–2 weeks, exposed on a
PhosphorImager 425E (GE Healthcare) and analysed using
MELANIE IV software (Swiss Institute of Bioinformatics,
Switzerland).
MS
2D-gels for mass spectrometric protein identiﬁcation,
loaded with cytoplasmic extract, were washed and vacuum
dried without any ﬁxation. Subsequently, the dried gels were
exposed to X-ray ﬁlms (GE Healthcare).
Protein spots of interest were excised from the gels and
digested with trypsin as described previously (Vandahl et al.,
2001). The digested protein spots were applied for auto-
mated nano-liquid chromatography tandem mass spectro-
metry (LC-MS/MS) analysis using an Ultimate (Dionex,
Amsterdam, the Netherlands) in-line connected to an
electrospray ionization (ESI) Esquire HCT ion trap (Bruker
Daltonics, Bremen, Germany) according to Stucke et al.
(2007). MS/MS fragmentation spectra were converted to
Mascot generic ﬁles (mgf) using the AUTOMATION ENGINE
software (version 3.2, Bruker Daltronics) and searched,
using a lab-installed version of MASCOT (version 2.1.0)
(http://www.matrixscience.com), against a C. trachomatis
L2 protein database. MASCOT’s parameter settings were as
follows: enzyme, trypsin; variable modiﬁcations, carbami-
domethyl (C), deamidation (NQ), oxidation (M) and pyro-
glu (N-term Q); peptide mass and fragment mass tolerances,
 0.5Da; maximum number of missed cleavages, 1; and
instrument type, ESI-TRAP. Only spectra that exceeded
MASCOT’s threshold score for identiﬁcation (set at a 95%
conﬁdence level) were further evaluated.
Bioinformatics
BLASTP searches were performed using a BLOSUM62 scoring
matrix withgapcostsof existence 11 andextension 1(http://
www.ncbi.nlm.nih.gov/BLAST/). The database Pfam 23.0
was used to search for conserved domains. A multiple
sequence alignment of CT621 homologues was created in
CLUSTALX using the PAM250 amino acid matrix (Higgins &
Sharp, 1988; Chenna et al., 2003). Based on this alignment, a
minimum evolutionary phylogenetic tree was constructed
using MOLECULAR EVOLUTIONARY GENETICS ANALYSIS (MEGA) soft-
ware, version 3.1 (Kumar et al., 2004). Sequences were also
compared in a dot plot, with the polydot application from
the EUROPEAN MOLECULAR BIOLOGY OPEN SOFTWARE SUITE (EMBOSS)
(Rice et al., 2000).
Cloning, expression and production of
polyclonal antibodies
Using the forward primer GACGACGACAAGATGAACCGT
ATTCATCGTACACAAGGATC and the reverse primer GA
GGAGAAGCCCGGTCTATCTTAAGAGATTACGCGCTAAT
CC, a PCR of ct621 was performed on C. trachomatis L2
DNA in a GeneAmp PCR system 9600 (Perkin Elmer,
Waltham, MA). The PCR programme was composed of 35
cycles of 941C for 30s, 551C for 30s and 721C for 1min,
and T4 DNApolymerase (Novagen, Madison, WI) was used.
The ampliﬁed DNA product was puriﬁed using Wizard
(Promega, Madison, WI). Following this, cloning and ex-
pression of the hexahistidine-tagged protein was performed
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manufacturer’s instructions. The hexahistidine-tagged fu-
sion protein was puriﬁed on Ni
21 HiTrap
TM chelating HP
columns (GE Healthcare) as described (Mygind et al., 1998).
To raise polyclonal antibodies, rabbits were immunized
three times intramuscularly with 100mg fusion protein and
incomplete Freund’s adjuvant (IFA), and three times intra-
venously with 100mg of the fusion protein without IFA
(Shaw et al., 2002).
Immunofluorescence microscopy
HeLa cells, cultivated on coverslips, were infected with
0.5IFU per cell of C. trachomatis L2 and ﬁxed in parafor-
maldehyde/glutaraldehyde as described (Vandahl et al.,
2005). Fixations were performed at different points in time,
ranging from 12 to 46hpi. Primary antibodies, PAb245
against CPAF (Shaw et al., 2002) (1:200 dilution) or
PAb342 against CT621 (1:500 dilution), were used and
visualized using ﬂuorescein isothiocyanate (FITC)-conju-
gated goat anti-rabbit secondary antibodies (1:200 dilu-
tion) (Jackson ImmunoResearch Laboratories, West Grove,
PA). For double-stainings, mouse monoclonal MAb32.2
recognizing MOMP (Birkelund et al., 1988) was used (1:40
dilution), together with rhodamine-conjugated goat anti-
mouse secondary antibodies (1:100 dilution) (Jackson
ImmunoResearch Laboratories). Host cell nuclei were vi-
sualized using 40,6-diamidino-2-phenylindole (DAPI).
Images were obtained using a Leitz DMRBE ﬂuorescence
microscope (Leica, Heidelburg, Germany) connected to a
Sony 3CCD colour video camera. The objective used was a
Leica HCX PL APO  100/1.40 oil lens (Leica).
Purification of C. trachomatis L2 EB
Chlamydia trachomatis L2-infected HeLa cell monolayers
were scraped off in 4-2-hydroxyethyl-1-piperazineethane-
sulphonic acid at 38hpi. After the cell debris was spun
down, the supernatant was treated with DNAse and RNAse.
Chlamydia trachomatis EB were puriﬁed by two rounds of
density gradient ultracentrifugation through Visipaque (Ny-
comed, Roskilde, Denmark) gradients, essentially as de-
scribed in (Schachter & Wyrick, 1994).
Immunoblotting
Ten percent SDS polyacrylamide gels were loaded with
puriﬁed C. trachomatis EB, lysates of infected and unin-
fected cells or proteins from each of the four extracted
fractions, and electroblotted onto polyvinylidene ﬂuoride
membranes. For immuno-detections, PAb342 raised against
CT621 was used in a 1:500 dilution. Secondary alkaline
phosphatase-conjugated goat anti-rabbit antibodies (Sigma-
Aldrich, St. Louis, MO) were applied in a dilution of
1:30000.
Inhibition of the chlamydial T3SS
The T3SS inhibitor N0-(3,5-dibromo-2-hydroxybenzyli-
dene)-4-nitrobenzohydrazide, C1 (ChemBridge, San Diego,
CA), was dissolved in dimethyl sulphoxide (DMSO), and
then 10 or 50mM of this inhibitor was added at 30, 32 or
34hpi to the medium of C. trachomatis L2-infected HeLa
cells (0.5IFU per cell) cultured on coverslips. The DMSO
concentration in the infection medium was maintained
below 0.1% in all the experiments. Cells were ﬁxed at
36hpi and the localization of CT621 and MOMP was
visualized using immunoﬂuorescence microscopy with anti-
bodies as described above. Control cells were subjected to a
similar treatment, with the exception that pure DMSO was
applied, in corresponding concentrations instead of C1.
Results
2D-PAGE analysis of the cytoplasmic extract
from infected host cells
HeLa cells were infected with C. trachomatis L2, and from 36
to 38hpi, the chlamydial proteins were labelled with [
35S]-
methionine/cysteine in the presence of the eukaryotic pro-
tein synthesis inhibitor, cycloheximide. The cells were then
either harvested in 2D-lysis buffer or subjected to cytoplas-
mic extraction with subsequent protein precipitation and
resuspension of the pellet in 2D-lysis buffer. The proteins
from these samples were separated using 2D-PAGE. Auto-
radiographs of 2D-PAGE proﬁles of the separated chlamy-
dial proteins fromthe cytoplasmicextract (Fig.1a) and from
the lysate of infected cells (Fig. 1b) were compared. Poten-
tially secreted chlamydial proteins were found in higher
amounts in the cytoplasmic extract than in the lysate of
infected cells because the extraction of cytoplasmic proteins
results in their relatively higher concentration. This is
indicated by the presence of the secreted N- and C-terminal
parts of CPAF with the respective pI 7.3/25kDa and pI 4.8/
36kDa (Shaw et al., 2002) in both the 2D-PAGE proﬁle of
cytoplasmic extract (Fig. 1a and c) and that of the lysate of
infected cells (Fig. 1b and d indicated by hollow arrows),
with protein spots most visible in the cytoplasmic extract
proﬁle (Fig. 1a). The protein content of these spots was
veriﬁed using MS/MS (data not shown). Further, compar-
ison of the 2D-PAGE proﬁles revealed another protein spot,
with the estimated molecular coordinates pI 4.8/26kDa,
clearly present in the cytoplasmic extract (indicated by a
solid arrow inFig. 1a and c), but absent from the lysate of
infected host cells (Fig. 1b and d). Because of its abundance
in the cytoplasmic extract, this observed protein spot was
investigated further.
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The protein spot, which represented a potentially secreted
chlamydial protein, was excised and trypsin digested before
analysis using automated LC-MS/MS. Peptides from the
hypothetical C.trachomatis L2protein,CT621,were identiﬁed
(bold letters, Fig. 2). In the present paper, we used the
annotated C. trachomatis D genome for numbering the
C. trachomatis L2 genes. In the annotated C. trachomatis L2
genome, the CT621 gene is CTL0885. A theoretical pI/Mw of
pI 4.92/92.7kDa was calculated for full-length CT621 using
the pI/Mw tool on the ExPASy server (http://www.expasy.ch/
tools/pi_tool.html). No clear protein spot with these molecu-
lar coordinates was found on the autoradiographs (Fig. 1), but
a 26-kDafragment of CT621was identiﬁed (Fig. 2), indicating
that the protein present in the host cell cytoplasm was cleaved.
CT621 homologues
Four C. trachomatis L2 proteins: CT619 (CTL0883), CT620
(CTL0884), CT711 (CTL0080) and CT712 (CTL0081), with
molecular weights of 97, 93, 86 and 44kDa, respectively,
showed homology to CT621. Like CT621, these proteins are
characterized by having a domain of unknown function,
DUF582, in their C-terminal region. In CT621, this domain
spans the region from amino acid 451 to 829 (dashed line,
Fig. 2). The domain is characterized by being leucine-rich,
and a leucine zipper is present in CT620 and CT621
(double-underlined, Fig. 2), indicating that these proteins
can form homo- or heterodimers. The remaining three
proteins within the DUF582 family do not contain the
leucine zipper but are rich in leucine. The CT621 homo-
logous proteins are present in the sequenced genomes of
Fig. 1. Autoradiographs of 2D-PAGE-separated
Chlamydia trachomatis L2 proteins labelled from
36 to 38hpi with [
35S]-methionine/cysteine in
the presence of cycloheximide. (a) Cytoplasmic
extract of infected HeLa cells. Hollow arrows
indicate CPAF C- and N-terminal parts. The solid
arrow indicates the 26-kDa CT621 cleavage
product. Regions surrounding these protein spots
areboxed. (b) Whole lysate of infected HeLa cells.
Boxed regions correspond to the regions
mentioned in (a). (c) Enlargement of the boxed
regions in (a), picturing the protein spots
representing the CT621 cleavage product and
both parts of CPAF. (d) Enlargement of the boxed
regions in (b).
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50 A.-S. Hobolt-Pedersen et al.C. trachomatis serovars A and D and in other chlamydial
species including Chlamydia abortus, Chlamydia caviae,
Chlamydia felis, Chlamydia muridarum and C. pneumoniae,
but not in Parachlamydia or in other bacteria. Based on a
multiple alignment of the related protein sequences per-
formed using CLUSTALX, a minimum evolution phylogenetic
tree was constructed using the MEGA 3.1 software (Fig. 3).
From a polydot plot created using EMBOSS, it was conﬁrmed
that no rearrangements had occurred. In the phylogenetic
tree, it is evident that, based on sequence similarities, the
proteins can be divided into four groups: CT620/CT621,
CT711, CT712 and CT619. Several chlamydial species are
represented in each of thesegroups,indicating that the genes
encoding CT620, CT711, CT712 and CT619 diverged before
the different chlamydial species. It is also seen that CT621
diverged from the CT620 group later during evolution than
the differentiation into the ﬁrst four protein groups oc-
curred. The development of CT621 probably occurred as a
duplication of the gene encoding CT620 and following
differentiation of this into CT621. At that point during
evolution, several chlamydial species were already segre-
gated, and therefore CT621 is seen only in C. trachomatis
and in the closely related C. muridarum (Everett et al.,
1999).
CT619, CT620 and CT621 are encoded in succession in
the chlamydial genome. Nevertheless, their genes are not
transcribed as an operon, because CT620 is encoded on the
opposite DNA strand (http://stdgen.northwestern.edu).
Immunofluorescence microscopy
In order to compare the subcellular localization of CT621
and CPAF in C. trachomatis L2-infected cells ﬁxed at 46hpi,
these proteins were visualized using polyclonal primary
antibodies and FITC-conjugated secondary antibodies [Fig.
4a and c (CT621) and Fig. 4b and d (CPAF)]. Localization of
the chlamydiae was shown using a MOMP-speciﬁc mono-
clonal antibody and rhodamine-conjugated secondary anti-
bodies, while host nuclei were stained with DAPI (Fig. 4a
and b). By displaying the FITC ﬂuorescence alone, the
distribution of CT621 and CPAF in the different compart-
ments of the host cell was revealed (Fig. 4c and d). The
corresponding Nomarsky images show the localization of
the chlamydial inclusions and the host nuclei (Fig. 4e and f).
At this point in time, CT621 could be detected in both the
cytoplasm and the nuclei of most infected cells, although
some CT621 was retained inside the chlamydiae. The
retained CT621 is visualized as green spots within the
inclusion (Fig. 4c), while the RB surrounding the periphery
of the inclusion (Fig. 4a, indicated by red MOMP staining)
is devoid of CT621 (Fig. 4c). In contrast, CPAF is seen solely
within the host cell cytoplasm, and the inclusion shows no
CPAF staining 46hpi (Fig. 4b and d). These results demon-
strate that in contrast to CPAF, which is secreted only into
the cytoplasm, CT621 is secreted both into the host cell
cytoplasm and the nucleus. However, not all of the chlamy-
diae had secreted CT621.
During the infection of HeLa cells with C. trachomatis L2,
cycloheximide was added to the medium to facilitate this
process. To ensure that the exposure to cycloheximide was
not affecting the HeLa cells to an extent in which degrada-
tion of all CT621 in the cytoplasm was prevented, the
immunoﬂuorescence analysis was performed again without
the eukaryotic protein synthesis inhibitor. CT621 could still
be found in both the host cytoplasm and nucleus, indicating
that cycloheximide did not have an inﬂuence on the levels of
secreted CT621 (data not shown).
To determine at which point during the chlamydial
developmental cycle CT621 was secreted, C. trachomatis
L2-infected cells were ﬁxed at different points in time
ranging from 12 to 46hpi. With immunoﬂuorescence
microscopy, it was revealed that no CT621 was secreted
before 32hpi (Fig. 5). Subsequently, at later time points,
more and more CT621 was secreted into both host cell
cytoplasm and nuclei, and from 38hpi, CT621 was secreted
into almost all infected cells. MOMP was visualized by
rhodamine (red) ﬂuorescence and CT621 by FITC (green)
ﬂuorescence (Fig. 5a–e). Pictures showing the FITC
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661 DVFLEITKAA KTTVTNQQSA VTDDDKLSTE QKAKINAELT QYTDMLNAIN NSLTSLKTQL
721 APLSVSTVEG VDGVFEVKNG KPGENGKNWR LVLQTLEDTV VSGEVGSPTN IGMFQMQALV
781 HSNQQAYADM GQNFQLELQM HLTSMQQEWM VVATSLQLLN QIYLGLARNL LR 
Fig. 2. Complete amino acid sequence of the
Chlamydia trachomatis L2 protein CT621. The
DUF582 domain is marked with a dashed line; the
leucine zipper is double-underlined, and peptides
identiﬁed with LC-MS/MS are shown in bold.
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51 Chlamydia trachomatis CT621 type III secretionﬂuorescence alone (Fig. 5f–j) as well as the corresponding
Nomarsky images were also analysed (Fig. 5k–o). At 32hpi,
CT621 could be detected as green spots overlapping with
MOMP within the inclusion (Fig. 5a and f). Subsequently at
34hpi, most of the CT621 was still localized in the chlamy-
dial inclusion, but a small amount of the protein was also
observed in the host cytoplasm (Fig. 5b and g). After 36h of
infection, CT621 was secreted and evenly distributed in the
host cytoplasm and nucleus as well as in the chlamydial
inclusion; however, inside the inclusion, the MOMP stain-
ing at the periphery (Fig. 5c) was stronger than the CT621
staining (Fig. 5h). At 38hpi and until the end of the
Fig. 3. Phylogenetic tree of CT621 protein
homologues. Based on a multiple alignment
performed in CLUSTALX, a phylogenetic tree was
constructed with the minimum evolution method
in MEGA 3.1. The ﬁve Chlamydia trachomatis
serovar L2 homologues are shown in bold. The
abbreviations used are listed: Chlamydia
trachomatis serovars: L2 (CtrL2), D (CtrD) and A
(CtrA); Chlamydia pneumoniae isolates: CWL029
(CpnCWL), AR39 (CpnAR), J138 (CpnJ), TW-183
(CpnTW), Chlamydia muridarum (Cmu),
Chlamydia caviae (Cca), Chlamydia felis (Cfe) and
Chlamydia abortus (Cab). Where identical
sequences are seen, only one isolate is listed.
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52 A.-S. Hobolt-Pedersen et al.experiment at 46hpi, CT621 was still found to be secreted.
As expected, neither CT621 nor MOMP was present in the
uninfected cells (Fig. 5c, h and m, indicated by arrows). In
additional immunoﬂuorescence microscopy analysis, CT621
was also found to be secreted in C. trachomatis D-infected
HeLa cells.
Immunoblotting
Both localization and the size of CT621 were veriﬁed by
immunoblotting performed on EB, lysates of infected and
uninfected cells and on cellular extracts, all harvested at
38hpi (Fig. 6). Polyclonal CT621-speciﬁc antibodies recog-
nized full-length CT621 in EB and in the lysate of infected
cells, while no reaction with uninfected HeLa cells was
observed. Fractionation of C. trachomatis L2-infected cells
was performed with extraction buffers I, II and III. Proteins
from these fractions and from the remaining cytoskeletal
fraction (IV) were separated by SDS-PAGE and subjected to
immunoblotting with CT621-speciﬁc antibodies (Fig. 6). In
the cytoplasmic extract, the full-length protein and frag-
ments of around 40 and 50kDa were found. Additionally,
full-length CT621 bands were observed in all other fractions;
however, the strongest staining was seen in the membrane/
organelle fraction (II) also containing chlamydial EB, and in
the nuclear fraction (III).
Inhibition of the chlamydial T3SS
To investigate the CT621 secretion pathway, the T3SS
inhibitor, C1, was added to C. trachomatis L2-infected cells
at different points in time. As described by Wolf et al. (2006)
and Muschiol et al. (2009), C1 affects chlamydial develop-
ment, and culturing of infected cells in a medium supple-
mented with C1 for longer time periods results in abnormal,
small chlamydial inclusions. However, when added at a later
point in time after infection, no such inﬂuence of C1 on
chlamydial growth was seen (Chellas-G´ ery et al., 2007). To
ensure the least exposure time of chlamydiae to the inhibi-
tor, the addition of C1 was scheduled a few hours before
ﬁxation of the infected cells. C1 was added to C. trachomatis
L2-infected cells at 30, 32 or 34hpi, before ﬁxation at 36hpi.
The ﬁxation time was set at 36hpi, because CT621 was
clearly visible in the host cell cytoplasm at this time after
Fig. 4. Subcellular localization of CT621 (a, c)
and CPAF (b, d) in Chlamydia trachomatis
L2-infected HeLa cells ﬁxed with
paraformaldehyde/glutaraldehyde at 46hpi.
(a, b) CT621 and CPAF are visualized in double
stainings using antibodies directed against each
of these proteins and against MOMP. The
presence of CT621 and CPAF was revealed using
FITC (green)-conjugated secondary antibodies
and MOMP using rhodamine (red)-conjugated
secondary antibodies. DNA was stained with
DAPI (blue). (c, d) FITC channel shown separately.
(e, f) Corresponding Nomarsky images. Scale
bar=10mm.
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53 Chlamydia trachomatis CT621 type III secretioninfection (Fig. 5c and h). C1 concentrations of 10 and 50mM
were used, and after ﬁxation, immunoﬂuorescence
microscopy was performed (Fig. 7). When 10mM C1 was
added at 30 or 32hpi, no CT621 was found in the host
cytoplasm at 36hpi; instead, it was retained within the
chlamydiae, where it can be seen as green spots overlapping
with MOMP (red) (Fig. 7a, b, d and e). In contrast, if the
T3SS inhibitor was added at 34hpi, CT621 was localized in
the host cytoplasm and nucleus (Fig. 7c and f). This
indicates that CT621 secretion is initiated between 32 and
34hpi. Parallel Nomarsky images (Fig. 7g–i) show the
inclusions and nuclei within the host cells. There was no
indication of impaired integrity of the chlamydial inclusion
membrane.
Ten micromolars of C1 was sufﬁcient to cause the
inhibition of CT621 secretion, and a similareffect was found
with 50mM C1 at all points in time. Control treatments of
Fig. 5. Immunoﬂuorescence microscopy of
Chlamydia trachomatis L2-infected cells ﬁxed
with paraformaldehyde/glutaraldehyde at
different points in time after infection. (a–e)
Double stainings with primary antibodies against
CT621 and MOMP, visualized using FITC
(green)-conjugated and rhodamine
(red)-conjugated secondary antibodies,
respectively. (f–j) FITC channel shown separately.
(k–o) Corresponding Nomarsky images. White
arrows indicate an uninfected cell in which
neither CT621 nor MOMP can be detected (c, h
and m). CT621 secretion is initiated between 32
and 34hpi. Scale bar=10mm.
Fig. 6. Immunoblotting with CT621-speciﬁc antibodies. The inserted
scale is created using stained Mark 12 molecular size markers. Polyviny-
lidene ﬂuoride membranes containing EB: puriﬁed Chlamydia trachoma-
tis EB; IC, lysate of infected cells; UC, lysate of uninfected cells; I,
cytoplasmic extract; II, membrane/organelle/EB fraction; III, nuclear
fraction; and IV, cytoskeletal fraction were reacted with anti-CT621
polyclonal antibodies.
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54 A.-S. Hobolt-Pedersen et al.infected cells with the C1 solvent, DMSO, did not affect the
secretion of CT621.
Discussion
Based on the results obtained by 2D-PAGE, immunoﬂuor-
escence microscopy and immunoblotting, a secreted chla-
mydial protein was identiﬁed. Previously, we have shown
that extraction buffer I from the ProteoExtract
TM subcellu-
lar proteome extraction kit can be used to isolate the
cytoplasm from C. trachomatis L2-infected HeLa cells with-
out rupturing the chlamydial membranes and without
extracting the eukaryotic organelles (Hobolt-Pedersen
et al., 2006). Abundant chlamydial proteins such as MOMP
can be detected when the cytoplasmic fraction is analysed by
2D-PAGE, but even though some rupturing of chlamydiae is
unavoidable during the extraction procedure, the chlamy-
dial proteins secreted are still much more concentrated in
the cytoplasmic extract than in the lysate of infected cells.
This is indicated by the presence of CPAF C- and N-terminal
parts, with more intense spots on the 2D-PAGE proﬁle of
the cytoplasmic extract compared with the corresponding
spots on the proﬁle of the lysate of infected cells (Fig. 1).
Comparison of 2D-PAGE proﬁles also led to the identiﬁca-
tion of a 26-kDa fragment of CT621. CT621 was ﬁrst
described by Skipp et al. (2005), who, using proteomics,
identiﬁed the protein as being speciﬁc for RB. However,
none of the other protein family members were described in
these investigations.
In the present study, a fragment of CT621 was found in
the host cytoplasmic extract, indicating that the protein is
cleaved there. This was conﬁrmed using immunoblotting
with antibodies raised against CT621 (Fig. 6), together with
full-length CT621; different cleavage products were found in
the cytoplasmic fraction. In the nuclear extract, however,
nearly only full-length CT621 was seen (Fig. 6). Immuno-
ﬂuorescence microscopy showed that CT621 is localized to
both the cytoplasm and the nucleus of C. trachomatis L2-
infected HeLa cells. Thus, CT621 is the ﬁrst chlamydial
protein found in the host nucleus and this observation is
strongly supported by the results of the immunoblotting.
As no transformation system exists for the genetic ma-
nipulation of chlamydiae, other approaches must be used to
study the localization and the potential function of chlamy-
dial proteins. Sisko et al. (2006) used the expression of
Chlamydia-speciﬁc genes inyeasttodetermine whether such
proteins could impair various yeast cell functions. They,
furthermore, determined whether any of the proteins were
translocatedtothecellsurface,nucleusorotherorganelles.Of
the DUF582 family, four proteins were expressed,but none of
them showed nuclear localization. CT620 and CT711 were
seen in the yeast cytoplasm, CT712 showed punctuated
cytoplasmic staining while CT621 showed cytoplasmic aggre-
gates. That CT621 was not translocated to the yeast nucleus
may be explained by the use of an artiﬁcial system in which
CT621 aggregated within the yeast cytoplasm.
Using immunoﬂuorescence microscopy, it was revealed
that the secretion of CT621 is initiated between 32 and
Fig. 7. Immunoﬂuorescence microscopy
showing the effects of addition of 10mMo ft h e
T3S inhibitor, C1, to Chlamydia trachomatis L2-
infected cells at 30, 32 or 34hpi. At 36hpi,
all the cells were ﬁxed with paraformaldehyde/
glutaraldehyde. (a–c) Double stainings with
primary antibodies against CT621 and MOMP,
visualized using FITC (green)-conjugated and
rhodamine (red)-conjugated secondary
antibodies, respectively. (d–f) FITC channel
shown separately. (g–i) Corresponding Nomarsky
images. Scale bar=10mm.
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55 Chlamydia trachomatis CT621 type III secretion34hpi. At 34hpi, a small amount of CT621 was found to be
secreted, and this amount increased until 36hpi, where it
was evident that CT621 is secreted into both the host cell
cytoplasm and the nuclei of the infected cells. CT621 is
secreted late in the chlamydial developmental cycle, indicat-
ing that the protein has a function in the later stage of
infection. In contrast to what was seen for CPAF, the
inclusions contained CT621 at all points in time after
secretion could ﬁrst be observed (Fig. 5). It is therefore
possible that secretion of CT621 continues after the initial
secretion. Our suggestion that CT621 functions late in the
chlamydial developmental cycle ﬁnds support in the geno-
mic transcriptional analysis performed by Belland et al.
(2003). In this study, microarrays were used to investigate
gene expression in C. trachomatis D at different develop-
mental stages, and it was shown that the expression of the
CT621 gene was most profound from 24hpi and later in the
chlamydial developmental cycle. Furthermore, the gene
encoding the CT621 homologue, CT712, was deﬁned as a
late gene.
Addition of the chlamydial T3SS inhibitor, C1, to
C. trachomatis L2-infected cells before the initiation of
CT621 secretion resulted in retention of the protein inside
the chlamydial inclusions. This C1 caused inhibition of
CT621 secretion, which indicates that the protein is trans-
ported into the eukaryotic host cell through the T3S path-
way. That CT621 is secreted through the T3SS is supported
by the ﬁndings of Subtil et al. (2005), who found that in
their heterologous Shigella system, CT712, which is also a
member of the DUF582 family, was secreted by the T3SS. A
new hypothesis implies that loss of contact between RB and
the inclusion membrane, coupled to T3SS inactivation,
triggers the late differentiation of Chlamydia (Peters et al.,
2007). This could mean that the T3SS is crucial in the
regulation of chlamydial growth and development inside the
host. The hypothesis is supported by the fact that exposure
to inhibitors of the T3SS such as C1 affects the chlamydial
development, probably because secretion of certain effectors
is altered (Wolf et al., 2006; Bailey et al., 2007; Peters et al.,
2007). In agreement with the described hypothesis, we
found indications that CT621 secretion through the T3SS
takes place from RB located close to the inclusion mem-
brane (Fig. 4a and c).
CT621 is the ﬁrst chlamydial protein shown to be
translocated to the nucleus of infected cells, even though
the nuclear localization, in theory, could be explained by
lateral diffusion. However, because CT621 is leucine rich,
full-length CT621 is found in the nuclear extract, and
because the two secreted fragments of CPAF of 25 and
36kDa are found only in the cytoplasm of chlamydial-
infected cells at the same time as CT621 is found in both
inclusions and in host cell cytoplasm and nuclei, we favour
that CT621 is translocated to the nucleus. The idea of
chlamydial proteins being translocated to the host cell
nucleus is supported by the study of Chellas-G´ ery et al.
(2007). In this study, it was shown that human Grap2 cyclin
D-interacting protein interacts with the chlamydial-speciﬁc
T3S effector protein CT847, a manipulating interaction that
could possibly take place in the host nucleus. Several type III
effectors, localized to the host cell nucleus, have been
identiﬁed in other gram-negative bacteria, and some of
these proteins inhibit the expression of host inﬂammatory
response genes. It is possible that CT621 has a similar
function and thereby can modulate the host immune
defence, although no common amino acid sequence simila-
rities between CT621 and any other such effectors could be
identiﬁed.
Within the DUF582 domain, CT621 and CT620 have a
leucine zipper with four leucine residuesat a ﬁxed spacing of
seven amino acids (Fig. 2, double-underlined). Leucine
zippers form protein dimers, resulting in the formation of
helical structures wrapped around each other in a coiled
coil, frequently associated with DNA binding (Landschulz
et al., 1988; Bornberg-Bauer et al., 1998). CT621 is not the
only type III effector for which a leucine-containing region
is characteristic; several other nuclear localizing type III
effectors have a leucine-rich region: for example, YopM,
IpaH9.8 and SspH1. It is suggested that the leucine-rich
regions are related to the nuclear translocation of these
proteins. Because CT621 is also localized within the nucleus
of infected cells, it can be speculated that the leucine-
containing region plays a similar role in this transport.
The DUF582 domain is speciﬁc to Chlamydia. The
CT619-, CT620-, CT711- and CT712-encoding genes are
found in all Chlamydia species, while the CT621-encoding
gene is found only in C. trachomatis and C. muridarum. The
gene family is strictly found in Chlamydia and was not
detected in the sequenced Parachlamydia genome. The
encoded proteins must have essential functions because the
family is found in all Chlamydia. However, the sequence
variation between the proteins indicates that they have
speciﬁc targets. Such targets must be present in all hosts
that can be infected by Chlamydia. For each protein, major
sequence variations are also found between species, indicat-
ing that the proteins have adapted to the respective hosts.
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